SP600125

Catalog No.S1460 Synonyms: Nsc75890

SP600125 Chemical Structure

Molecular Weight(MW): 220.23

SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 77 In stock
USD 247 In stock
USD 587 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

4 Customer Reviews

  • Loss of DUSP4 function upregulates IL-6 and IL-8 and enhances mammosphere growth. Immunoblot analysis of MDA-231 cells after treatment of 24 hours with 1 umol/L selumetinib (MEKi) or 10 umol/L SP600125 (JNKi). I, MDA-231 mammosphere formation quantitated by GelCount software 7 days after siRNA transfection. Where indicated, selumetinib (MEKi) or SP600125 (JNK1) or the combination was added to the mammosphere cultures.

    Cancer Res 2013 73(20):6346-58. SP600125 purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823(5), 987-96. SP600125 purchased from Selleck.

  • Bone marrow derived macrophages were pre-treated with the indicated concentrations of SP600125 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. SP600125 purchased from Selleck.

    SP600125 purchased from Selleck.

Purity & Quality Control

Choose Selective JNK Inhibitors

Biological Activity

Description SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc.
Targets
JNK1 [1]
(Cell-free assay)
JNK2 [1]
(Cell-free assay)
Aurora A [4]
(Cell-free assay)
TrkA [4]
(Cell-free assay)
JNK3 [1]
(Cell-free assay)
40 nM 40 nM 60 nM 70 nM 90 nM
In vitro

SP600125 is originally characterized as a selective ATP-competitive inhibitor of c-Jun N-terminal kinase JNK. In Jurkat T cells, SP600125 inhibits the phosphorylation of c-Jun with IC50 of 5 μM to 10 μM. In CD4+ cells, such as Th0 cells isolated from either human cord or peripheral blood, SP600125 blocks cell activation and differentiation and inhibits the expression of inflammatory genes COX-2, IL-2, IL-10, IFN-γ, and TNF-α, with IC50 of 5 μM to 12 μM. [1] However, later studies reveal that SP600125 also suppresses aryl hydrocarbon receptor (AhR) [2], Mps1 [3], and a panel of other serine/threonine kinases, including Aurora kinase A, FLT3, MELK, and TRKA [4]. In a mouse beta cells MIN6, SP600125 (20 μM) induces the phosphorylation of p38 MAPK and its downstream CREB-dependent promoter activation. [5] In HCT116 cells, SP600125 (20 μM) blocks the G2 phase to mitosis transition and induces endoreplication. This ability of SP600125 is independent of JNK inhibition, but due to its inhibition of CDK1-cyclin B activation upstream of Aurora A and Polo-like kinase 1. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Plasmodium falciparum HB3 MU\BcpRq[mGldHXybYFtKEG|c3H5 MnGzO|IhcA>? MUDEUXNQ NUO3N29wSW62aYDsZZNud2SrYXygZYN1cX[rdImge4l1cCCLQ{WwJI9nKDdwOUSzNlgh|ryP NV7Mb4p5OTl5M{S5NVA>
Plasmodium falciparum W2 M1PJdGFvfGmkYXP0[ZJq[WxiQYPzZZk> MYG3NkBp M3Xpe2ROW09? Mn:2RY51cXCuYYPtc4Rq[WxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFcvQTR|Mkig{txO MofuNVk4OzR7MUC=
Plasmodium falciparum 7G8 NXXiZ3l6SW62aXLhZ5RmemmjbDDBd5NigQ>? M2CzZVczKGh? M17qSmROW09? MWrBcpRqeGyjc33v[IlidCCjY4Tpeol1gSC5aYToJGlEPTBib3[gNVAh|ryP NYjBbnF{OTl5M{S5NVA>
Plasmodium falciparum 3D7 NF31e5JCdnSrYnHjeIVzcWGuIFHzd4F6 M4TmRlczKGh? MmfLSG1UVw>? M2mxTGFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IIfpeIghUUN3MDDv[kAyOi53OEmzJO69VQ>? NGXoc4UyQTd|NEmxNC=>
Plasmodium falciparum GB4 NWPaW204SW62aXLhZ5RmemmjbDDBd5NigQ>? MXG3NkBp NXLRfmNYTE2VTx?= M{jWTmFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IIfpeIghUUN3MDDv[kAyOi53OEmz{txO MVSxPVc{PDlzMB?=
RAW264.7 NFq5enFHfW6ldHnvckBCe3OjeR?= MX[xNEDPxE1? MWGxNkBp NFTDbWlCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOTgQvF2= NH:0TokyQTR7N{SxPC=>
SH-SY5Y MoLBSpVv[3Srb36gRZN{[Xl? MWGxNEDPxE1? NEmySJUyKGh? MYfEUXNQ M{GzNm5mfXKxcILveIVkfGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZiYX7pd49ugWOrbj3pcoR2[2WmIHPlcIwh\GWjdHi= NX\KOoQ{OjN2OUi5NVQ>
SH-SY5Y M3fPV2tqdmG|ZTDBd5NigQ>? M3zaWlExKM7:TR?= NYDobGtwOSCq MlnKSG1UVw>? MnPZTY5pcWKrdHnvckBw\iCMTluzJIF{e2W|c3XkJIF{KGKub3PrZYRmKG:oIHHubZNwdXmlaX6tbY5lfWOnZDDjMYp2diCyaH;zdIhwenmuYYTpc44h[XRic3XyO|M> M{nDWFI{PDl6OUG0
RAW264.7 NYPIZ|hzTnWwY4Tpc44hSXO|YYm= M{HIUlExKM7:TR?= MnfnNlQhcA>? MX\BcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiSVytNYJmfGFicnXs[YF{\Q>? M1zsU|I{PzlzMEe4
RAW264.7 NITXSHlHfW6ldHnvckBCe3OjeR?= MYCxNEDPxE1? NXnxTpZFOjRiaB?= NF3lUmFCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhcU6RUzDlfJBz\XO|aX;u MUSyN|c6OTB5OB?=
RAW264.7 MWTGeY5kfGmxbjDBd5NigQ>? MWKxNEDPxE1? MlHXNkBp NVG4b5pISW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb36= NUnxcJJ1OjN5OUGwO|g>
B16-F10 MXXGeY5kfGmxbjDBd5NigQ>? MWKxJIg> MUjJcohq[mm2aX;uJI9nKFSQRj3hcJBp[S2rbnT1Z4VlKGNvSmXOJJBpd3OyaH;yfYxifGmxbh?= M4[w[VIyQDF3NkO0
PC12 M4qydGZ2dmO2aX;uJGF{e2G7 MoP0NVAh|ryP NVzqXFhGPSCq M3\1NGROW09? NIfQdWFC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25icILleJJm[XSnZDD3bZRpKFCGOUiwOVk> NECwNG8zOTN2NU[4OS=>
PC12 M{\Lb2Z2dmO2aX;uJGF{e2G7 M2j5Z|ExKM7:TR?= MWS1JIg> NGnDUXNFVVOR NFy4NoRC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25icILleJJm[XSnZDD3bZRpKFVyMUK2 NE\XUmszOTN2NU[4OS=>
PC12 MWnGeY5kfGmxbjDBd5NigQ>? M{K4UFExKM7:TR?= MmLQOUBp NYGzNnJNTE2VTx?= NF;PR2ZC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25icILleJJm[XSnZDD3bZRpKFOSNkCwNVI2 NXfHe3hJOjF|NEW2PFU>
PC12 MV\GeY5kfGmxbjDBd5NigQ>? NGDzV5EyOCEQvF2= NHvnWIE2KGh? NVj2PIRoTE2VTx?= NV;5W25xSWO2aY\heIlwdiCxZjDOdoYzN0GURTDhd5Nme3OnZDDhd{BJVy1zIIDyc5RmcW5iaX7keYN1cW:wIIDy[ZRz\WG2ZXSge4l1cCCVQkKwN|U5OA>? MWKyNVM1PTZ6NR?=
A549 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rhdFIxKM7:TR?= NVjsbok4PzJiaB?= M2\mZ2ROW09? Mlq4VoFxcWRiYX7kJJBwfGWwdDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? M173XFI{QTF{OESw
PC3 M1X0XGZ2dmO2aX;uJGF{e2G7 Mn23NlUh|ryP M2ji[lI1KGh? NFnxfmRKdmirYnn0bY9vKG:oIFHQMVEh[W6mIICyNUBtfWOrZnXyZZNmKGGldHn2bZR6KGmwZIXj[YQh[nliU{G3PWQhWFKO MXGyN|E3OjZ3Mh?=
THP-1 NGLqPGtHfW6ldHnvckBCe3OjeR?= NF;lV286OCCwTR?= NYjKZmY5OzBibXnu NVHtZ3BrUW6qaXLpeIlwdiCxZjD0bZN{fWViZnHjeI9zKGW6cILld5Nqd25? NVPnU4lROjJ7NECwOVk>
LoVo NEnON|NHfW6ldHnvckBCe3OjeR?= MY[xJO69VQ>? NGfCOJkyKGh? NInUUJhKdmirYnn0bY9vKG:oIGDHSVIucW6mdXPl[EBmgHC{ZYPzbY9vKG:oIIXQRUBidmRiTV3QMVkhe2mpbnnmbYNidnSueR?= MoTYNlE5PTl2N{m=
LoVo NX3FRZRKTnWwY4Tpc44hSXO|YYm= NGSwTZUyKM7:TR?= MmLPNUBp Mk\GRoxw[2u|UFfFNk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIIPp[45q\mmlYX70cJk> NIe1NpMzOTh3OUS3PS=>
A549 NEnnXJNHfW6ldHnvckBCe3OjeR?= MoLvNlAh|ryP MWKxJIg> MmX1TY5pcWKrdHnvckBw\iCWUFGtbY5lfWOnZDDNUXAuOiCjbnSgeU1RSSCneIDy[ZN{cW:w NIXPeHAzODR7MkG3OS=>
HaCaT MVXGeY5kfGmxbjDBd5NigQ>? NEjMfHUzOCEQvF2= NEj1TWg1KGh? M3X1OGROW09? NFzEOHpDdG:la4OgeIhmKFSQRj5OtU1qdmS3Y3XkxsBEYVB2RkGxxsB1emGwc3PybZB1cW:w NYK4NWhDOTl6MUKzOFk>
HaCaT NYThNWVtTnWwY4Tpc44hSXO|YYm= NIe5[lczOCEQvF2= MVKyOEBp MVfEUXNQ NXPhOm9JSmyxY3vzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiYz3KeY4heHKxdHXpci=> MoLRNVk5OTJ|NEm=
PC3 MU\GeY5kfGmxbjDBd5NigQ>? NIDQNGUzOCEQvF2= MUSxJIg> NVfqSXh3TGWlcnXhd4V{KHSqZTDNUXAzKGGwZDDNUXA6KGW6cILld5Nqd25? MYSxPVY{Ozl5NR?=
BV-2 MYTGeY5kfGmxbjDBd5NigQ>? NHjFPYgzKM7:TR?= M1vlXVEhcA>? NVvBSYp4UW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJNDSU[IIILlcIVie2ViaX6gS41qgC22cnXheIVlKEKYLUKgZ4VtdHN? MmTGNVk1ODZ6M{G=
Hep3B NYLPVpE1TnWwY4Tpc44hSXO|YYm= M3L6UFExKM7:TR?= MV[xJIg> MWPCcI9kc3NiYYX0c5Bp[We7IHHu[EB2eHKnZ4XsZZRqd25ib3[gRoVkdGmwIEGg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KGOncnHtbYRm NYH1dVR2OTlyNkC5NlA>

... Click to View More Cell Line Experimental Data

In vivo In mice, SP600125 (15 mg/kg or 30 mg/kg) significantly inhibits lipopolysaccharide (LPS)-induced TNF-α expression and anti-CD3-induced apoptosis of CD4+ CD8+ thymocytes. [1]

Protocol

Kinase Assay:[4]
+ Expand

In Vitro Kinase Assays :

The potency of SP600125 towards kinases, including MPS1, JNK, and Aurora kinase A, is determined based on the specific measurement of radioactive phosphotransfer to the substrate. For each enzyme, the absolute Km values for ATP and the specific substrate are initially determined and each assay is then run at optimized [ATP] (2·αKm) and [substrate] (5·Km) concentrations. MPS1 activity is measured using 5 nM of MPS1 recombinant protein in 50 mM HEPES pH 7.5, 2.5 mM MgCl2, 1 mM MnCl2, 1 mM DTT, 3 μM NaVO3, 2 mM β-glycerophosphate, 0.2 mg/mL BSA, 200 μM P38-βtide substrate-peptide (KRQADEEMTGYVATRWYRAE), and 8 μM ATP with 1.5 nM 33P-γ-ATP. Ten serial 1:3 dilutions (from 30 μM to 1.5 nM) of SP600125 are tested and IC50 determined.
Cell Research:[4]
+ Expand
  • Cell lines: HCT116, A2780, and U2OS cells
  • Concentrations: 0–5 μM, dissolved in 0.1% DMSO
  • Incubation Time: 72 hours
  • Method: Cells are seeded in 384 well-plates. One day after seeding, the cells are treated with SP600125 for 72 hours and the plates are then processed using a CellTiter-Glo assay. Inhibitory activity is evaluated comparing treated versus control data and IC50 value of proliferation is calculated.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Mouse LPS/TNF model (female CD-1)
  • Formulation: Dissolved in PPCES (30% PEG-400/20% polypropylene glycol/15% Cremophor EL/5% ethanol/30% saline)
  • Dosages: 15 or 30 mg/kg
  • Administration: Administered via intravenous injection or orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 44 mg/mL (199.79 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 220.23
Formula

C14H8N2O

CAS No. 129-56-6
Storage powder
in solvent
Synonyms Nsc75890

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

JNK Signaling Pathway Map

Related JNK Products

Tags: buy SP600125 | SP600125 supplier | purchase SP600125 | SP600125 cost | SP600125 manufacturer | order SP600125 | SP600125 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID